Myomo Inc Cash Flow Conversion Efficiency
Myomo Inc cash flow conversion efficiency. Based on the latest financial reports, Myomo Inc (MYO) has a cash flow conversion efficiency ratio of -0.244x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.20 Million) by net assets ($9.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Myomo Inc (2014–2025)
Cash flow conversion efficiency of Myomo Inc from 2014 to 2025. This chart illustrates how Myomo Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Myomo Inc stock quote for real-time trading data and today's change.
Myomo Inc Cash Flow Conversion Ratio Explained
Myomo Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Myomo Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Myomo Inc ranked by their cash flow conversion efficiency. Also see MYO company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NextSource Materials Inc
TO:NEXT
|
-0.143x |
|
Orbit Garant Drilling Inc.
TO:OGD
|
-0.033x |
|
Foods & Inns Limited
NSE:FOODSIN
|
0.092x |
|
SGA Solutions Co.Ltd
KQ:184230
|
-0.097x |
|
Vishnu Prakash R Punglia Limited
NSE:VPRPL
|
0.089x |
|
GeneOne Life Science Inc
KO:011000
|
-0.056x |
|
Velocity Minerals Ltd
V:VLC
|
0.852x |
|
Grande Portage Resources Ltd
V:GPG
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Myomo Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Myomo Inc from 2014 to 2025. Review Myomo Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $11.40 Million | $-14.51 Million | -1.273x | -855.95% |
| 2024-12-31 | $24.71 Million | $-3.29 Million | -0.133x | +80.61% |
| 2023-12-31 | $8.99 Million | $-6.17 Million | -0.687x | +57.33% |
| 2022-12-31 | $6.36 Million | $-10.23 Million | -1.609x | -159.71% |
| 2021-12-31 | $15.41 Million | $-9.55 Million | -0.620x | +20.67% |
| 2020-12-31 | $11.57 Million | $-9.03 Million | -0.781x | +86.22% |
| 2019-12-31 | $1.82 Million | $-10.34 Million | -5.668x | -279.12% |
| 2018-12-31 | $6.43 Million | $-9.61 Million | -1.495x | -202.36% |
| 2017-12-31 | $12.45 Million | $-6.15 Million | -0.494x | -370.63% |
| 2016-12-31 | $-17.53 Million | $-3.20 Million | 0.183x | -92.67% |
| 2015-12-31 | $-1.34 Million | $-3.33 Million | 2.492x | +169.67% |
| 2014-12-31 | $712.11K | $-2.55 Million | -3.577x | -- |
About Myomo Inc
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.… Read more